tetano
Editor, Senior Moderator
Sci Rep
. 2025 Mar 27;15(1):10586.
doi: 10.1038/s41598-025-95479-9. Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses
Sharmistha Dam[SUP] 1 [/SUP], Alina Tscherne[SUP] 2 3 [/SUP], Leoni Engels[SUP] 1 [/SUP], Gerd Sutter[SUP] 2 3 [/SUP], Albert D M E Osterhaus[SUP] 1 [/SUP], Guus F Rimmelzwaan[SUP] 4 [/SUP]
Affiliations
The availability of influenza vaccines that can induce broadly protective immune responses is highly desirable and could also mitigate the impact of future influenza pandemics. Ideally, these vaccines also induce virus-specific CD8 + T cells, which have been identified as an independent correlate of protection. In the present study, we explored the use of an artificial immunogen that comprises of twenty highly conserved influenza virus CD8 + T cell epitopes with an HLA coverage of 99.5% of the world population. The highly attenuated viral vector Modified Vaccinia virus Ankara (MVA) was used to deliver the artificial poly-epitope sequence (rMVA-PE) and by using T cell lines raised against individual epitopes, we confirmed that the epitopes are liberated from the artificial immunogen. For efficient antigen processing and presentation, the epitopes were separated by spacer sequences. Stimulation of peripheral blood mononuclear cells of HLA-typed blood donors with rMVA-PE resulted in the activation of influenza virus-specific T cell responses. Furthermore, immunization of humanized HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice (HLA-A*02:01) with rMVA-PE induced influenza virus-specific CD8 + T cell responses. Thus, rMVA-PE proved to be immunogenic both in vitro and in vivo and constitutes a promising vaccine candidate for the induction of cross-reactive CD8 + T cell responses that could afford protection against antigenically distinct influenza A viruses (IAV) of various subtypes and species, and is currently considered for further clinical testing.
Keywords: CD8 + T cells; Conserved epitope; Cross-reactivity; Influenza virus; Universal vaccine.
. 2025 Mar 27;15(1):10586.
doi: 10.1038/s41598-025-95479-9. Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses
Sharmistha Dam[SUP] 1 [/SUP], Alina Tscherne[SUP] 2 3 [/SUP], Leoni Engels[SUP] 1 [/SUP], Gerd Sutter[SUP] 2 3 [/SUP], Albert D M E Osterhaus[SUP] 1 [/SUP], Guus F Rimmelzwaan[SUP] 4 [/SUP]
Affiliations
- PMID: 40148547
- DOI: 10.1038/s41598-025-95479-9
The availability of influenza vaccines that can induce broadly protective immune responses is highly desirable and could also mitigate the impact of future influenza pandemics. Ideally, these vaccines also induce virus-specific CD8 + T cells, which have been identified as an independent correlate of protection. In the present study, we explored the use of an artificial immunogen that comprises of twenty highly conserved influenza virus CD8 + T cell epitopes with an HLA coverage of 99.5% of the world population. The highly attenuated viral vector Modified Vaccinia virus Ankara (MVA) was used to deliver the artificial poly-epitope sequence (rMVA-PE) and by using T cell lines raised against individual epitopes, we confirmed that the epitopes are liberated from the artificial immunogen. For efficient antigen processing and presentation, the epitopes were separated by spacer sequences. Stimulation of peripheral blood mononuclear cells of HLA-typed blood donors with rMVA-PE resulted in the activation of influenza virus-specific T cell responses. Furthermore, immunization of humanized HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice (HLA-A*02:01) with rMVA-PE induced influenza virus-specific CD8 + T cell responses. Thus, rMVA-PE proved to be immunogenic both in vitro and in vivo and constitutes a promising vaccine candidate for the induction of cross-reactive CD8 + T cell responses that could afford protection against antigenically distinct influenza A viruses (IAV) of various subtypes and species, and is currently considered for further clinical testing.
Keywords: CD8 + T cells; Conserved epitope; Cross-reactivity; Influenza virus; Universal vaccine.